GRAIL, Inc. Financing Receivable, Credit Loss, Expense (Reversal)
GRAIL, Inc. (GRAL) reported Financing Receivable, Credit Loss, Expense (Reversal) of $332.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ProvisionForLoanLossesExpensed · last filed 2026-03-12
- GRAIL, Inc. financing receivable, credit loss, expense (reversal) for fiscal 2025 was $332.00K.
- GRAIL, Inc. financing receivable, credit loss, expense (reversal) for fiscal 2024 was $0.00.
- GRAIL, Inc. financing receivable, credit loss, expense (reversal) for fiscal 2023 was $0.00.
| Period end | Financing Receivable, Credit Loss, Expense (Reversal) 12 month |
|---|---|
| 2025-12-31 | $332.00K 10-K · filed 2026-03-12 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-12 |
| 2023-12-31 | $0.00 10-K · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |